Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities

Biocon partners with Tabuk to commercialize its Glucagon-like peptide-1 products in the Middle East

Aster’s India and GCC business separation nearing completion

The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value

Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine

Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy

Venus Remedies secures marketing approval from Israel, Colombia for two oncology drugs

The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia

Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries

10+ emerging markets, Japan & ANZ transition in final phase

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams

Venus Remedies expands reach with the launch of Elores in Ecuador

The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries

Venus Remedies launches its flagship R&D drug Elores in Oman

The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries